SRZNSurrozen, Inc./DEvs its industry peers
A metric-by-metric comparison of Surrozen, Inc./DE against Biological Products, (No Diagnostic Substances) — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| Empresa | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SRZNEsta | $200M#8 | — | — | 57.6x#9 | -67.4%#7 | -280.8%#13 | -1210.6%#9 | — | — | — | 43.8%#3 | — |
| STRO | $254M#1 | — | — | 2.5x#1 | 65.2%#2 | 15.9%#5 | -154.5%#4 | — | — | — | — | — |
| LIMN | $238M#2 | — | 793.1x#11 | — | — | -187.8%#12 | — | -3395.2%#11 | -170.3%#3 | — | — | — |
| TARA | $219M#5 | — | 1.4x#3 | 74.2x#10 | — | -28.7%#9 | -2189.6%#10 | -35.6%#4 | — | — | 21.3%#6 | — |
| PLX | $217M#6 | 11.7x#1 | 3.0x#5 | 4.1x#2 | -1.2%#4 | -325.2%#14 | -10.4%#1 | -9.2%#2 | -12.3%#1 | 3#1 | 46.2%#2 | — |
| IVVD | $221M#4 | — | 1.2x#2 | 4.1x#3 | 110.5%#1 | 69.1%#3 | -104.0%#2 | -29.0%#3 | — | — | -35.2%#11 | — |
| AVXL | $226M#3 | — | 2.0x#4 | — | — | -7.8%#6 | — | -41.2%#6 | — | — | -72.3%#14 | — |
| ALEC | $208M#7 | — | — | 9.9x#7 | -79.1%#8 | -20.2%#8 | -741.3%#8 | — | — | — | -36.7%#12 | — |
| ACOG | $191M#10 | — | 3.6x#8 | 18.7x#8 | — | -39.8%#10 | -221.7%#5 | -39.0%#5 | — | — | 5.0%#7 | — |
| VYGR | $186M#11 | — | 1.2x#1 | 4.6x#5 | -49.5%#5 | -84.2%#11 | -326.6%#6 | -77.6%#7 | — | — | -29.2%#9 | — |
| CHRS | $193M#9 | — | 3.2x#6 | 4.6x#4 | 59.8%#3 | 489.4%#1 | -429.5%#7 | 276.2%#1 | -351.2%#4 | — | -7.7%#8 | — |
| ABOS | $186M#12 | — | 3.3x#7 | — | — | -18.6%#7 | — | -211.9%#10 | -421.4%#5 | — | 104.4%#1 | — |
| DTIL | $178M#13 | — | 3.9x#9 | 5.2x#6 | -50.1%#6 | -738.0%#15 | -152.2%#3 | -101.0%#8 | — | — | 41.2%#5 | — |
| OTLK | $167M#14 | — | — | 118.0x#12 | — | 17.2%#4 | -4744.3%#11 | — | -12.8%#2 | — | -33.5%#10 | — |
| HUMA | $158M#15 | — | 5.1x#10 | 77.6x#11 | — | 72.5%#2 | -5306.0%#12 | -130.6%#9 | — | — | -62.8%#13 | — |
| ARMP | $155M#16 | — | — | — | — | -818.8%#16 | — | — | — | — | 41.5%#4 | 0.1%#1 |
Peer set: US filers sharing this company's SEC industry classification (SIC 2836). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Table built 2026-09-17.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice